 CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 GLOBE NEWSWIRE -- Black Diamond Therapeutics, Inc. Nasdaq: BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Companys development candidate for the treatment of glioblastoma multiforme GBM, as well as the commencement of Investigational New Drug IND-enabling studies. 